Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531565 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRFGFR4TDP1BLM | |
| Hydrochloric Acid SCHEMBL6419361 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TSHRFGFR4TDP1 | |
| SCHEMBL45578 | 0.82 | TSHR (0.34) | ALDH1A1TSHRFGFR4BLMSLC6A2 | |
| SCHEMBL30215 | 0.77 | TDP1 (0.36) | ALDH1A1TSHRFGFR4TDP1BLM | |
| SCHEMBL27631768 | 0.77 | TDP1 (0.36) | ALDH1A1TSHRFGFR4TDP1BLM | |
| SCHEMBL5708939 | 0.76 | TDP1 (0.35) | ALDH1A1TSHRFGFR4TDP1 | |
| SCHEMBL1345206 | 0.73 | — | — | |
| SCHEMBL4347745 | 0.73 | — | — | |
| SCHEMBL3947305 | 0.72 | TDP1 (0.32) | TDP1 | |
| Acrylic Acid SCHEMBL28100071 | 0.72 | LMNA (0.40) | ALDH1A1TSHRFGFR4TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005089106-A2 | DEGRADABLE NANOPARTICLES | MOLECULAR THERAPEUTICS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050196343-A1 | Polyacrylamide backbone; drug delivery, imaging, diagnosis; easily eliminated by body | MOLECULAR THERAPEUTICS, INC. (US) | 2005-09-08 | — | — | US | claimed |
| WO-2005089106-A2 | DEGRADABLE NANOPARTICLES | MOLECULAR THERAPEUTICS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050196343-A1 | Polyacrylamide backbone; drug delivery, imaging, diagnosis; easily eliminated by body | MOLECULAR THERAPEUTICS, INC. (US) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050196343-A1 | Polyacrylamide backbone; drug delivery, imaging, diagnosis; easily eliminated by body | ECPAS, ACTB, SERPINB10 | ALDH1A1 1098/4885TSHR 3798/4885FGFR4 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.